Sherene Loi

Research interests

Publications

• Embracing cancer complexity: Hallmarks of systemic disease

  Cell · 2024 · https://doi.org/10.1016/j.cell.2024.02.009

• Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2202809

• Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

  The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(22)02420-5

• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.019

• Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

  Journal for ImmunoTherapy of Cancer · 2020 · 10.1136/jitc-2019-000337

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

  The Lancet · 2020 · https://doi.org/10.1016/s0140-6736(20)32531-9

• Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

  Journal of Clinical Oncology · 2019 · 10.1200/jco.18.01010

• Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1914609

• Neoantigen-directed immune escape in lung cancer evolution

  Nature · 2019 · 10.1038/s41586-019-1032-7

• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1810527

• HER kinase inhibition in patients with HER2- and HER3-mutant cancers

  Nature · 2018 · 10.1038/nature25475

• Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1809615

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000161

• Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000162

• Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30516-8

• Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.67.3061

• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00613-0

• Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1505270

• Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

  Journal of Clinical Oncology · 2014 · 10.1200/jco.2014.58.1967

• Consensus guidelines for the detection of immunogenic cell death

  OncoImmunology · 2014 · 10.4161/21624011.2014.955691

• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu450

• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

  Annals of Oncology · 2014 · 10.1093/annonc/mdu112

• CD4+ follicular helper T cell infiltration predicts breast cancer survival

  Journal of Clinical Investigation · 2013 · 10.1172/jci67428

• Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2011.41.0902

• Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series

  Clinical Cancer Research · 2007 · 10.1158/1078-0432.ccr-06-2765

• Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

  JNCI Journal of the National Cancer Institute · 2006 · https://doi.org/10.1093/jnci/djj052

• Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

  JNCI Journal of the National Cancer Institute · 2006 · 10.1093/jnci/djj329

Current projects

No projects listed.